# Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2

> **NCT05844436** · — · AVAILABLE · sponsor: **AiCuris Anti-infective Cures AG**

## Conditions studied

- HSV

## Interventions

- **DRUG:** Pritelivir

## Key facts

- **NCT ID:** NCT05844436
- **Lead sponsor:** AiCuris Anti-infective Cures AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844436, "Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05844436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*